Active Filter(s):
Details:
EMD Serono also initiated a global Phase II study to further assess berzosertib in combination with topotecan for the treatment of relapsed, platinum-resistant SCLC (DDRiver SCLC 250).
Lead Product(s): Berzosertib
Therapeutic Area: Oncology Product Name: M6620
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.
Lead Product(s): Berzosertib,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: M6620
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types of tumors.
Lead Product(s): Berzosertib
Therapeutic Area: Infections and Infectious Diseases Product Name: M6620
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: UCLA Jonsson Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021